Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTMark NicholsTue, August 11, 2026 at 5:18 PM GMT+2 4 min readSpirax Gets Punished for Being Merely Good - MobyTHE GISTOur analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.Spirax did what it said it would do. The problem is investors wanted it to do more. Shares slid because the industrial engineer delivered progress without raising the bar, and in this market, "steady" can still get you whacked.WHAT HAPPENEDSpirax shares fell as much as 10% after the group reported first-half results and left its full-year guidance unchanged.Revenue rose 5% to £863.8 million (about $1.2 billion) in the six months to June 30, comfortably ahead of the company's internal benchmark for industrial production growth of around 1.5%.Statutory operating profit jumped 44% to £154.2 million, helped by a comparison with restructuring costs taken last year. On an adjusted basis, operating profit rose 8% to £171.1 million, while adjusted pre-tax profit increased 9% to £152 million.Adjusted operating margin ticked up to 19.8%, from around 19.3% to 19.7% depending on the measure used. The company reiterated guidance for mid-single-digit organic revenue growth and full-year margin progress, with management expecting the margin to move above 20%. All three divisions grew.Electric Thermal Solutions was the strongest, with sales up 11% as semiconductor demand improved. Watson-Marlow Fluid Technology Solutions grew 7%, helped by better momentum in biopharma. Steam Thermal Solutions, which accounts for around half of group sales, grew just 1%, weighed down by shipment phasing and weaker project activity in China.Cash conversion softened to 54% from 61%, partly due to seasonal timing and planned inventory builds. The interim dividend rose 3% to 50.4p.CEO Nimesh Patel said Spirax had delivered resilient growth ahead of industrial production and pointed to momentum in semiconductors and biopharma heading into the second half.WHY IT MATTERSSpirax is a classic "quality industrial" stock learning a classic quality-stock lesson: valuation matters when momentum disappoints.The company did not have a bad half. It grew revenue, improved profits, lifted margins, raised the dividend and kept guidance intact. That would usually count as a solid update. But Spirax has historically been priced for something better than solid.This is a business investors have liked because of its specialist engineering niches, high-margin aftermarket revenue and exposure to resilient industrial processes. Steam systems, thermal energy equipment and fluid technology are not fashionable in the same way as AI chips or obesity drugs, but they are embedded in industries that need reliability more than hype. That's the appeal. The trouble is that the recovery is uneven.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info